Previous studies have shown that atrial natriuretic factor, a powerful vasorelaxant of precontracted vessels, inhibits the secretion of aldosterone stimulated by angiotensin II, adrenocorticotropic hormone, and potassium. We now report the presence of specific binding sites for atrial natriuretic factor in rat blood vessels (mesenteric and renal arteries) and adrenal capsules. Radioiodinated synthetic atrial natriuretic factor bound to a single class of high-affinity (K D = 0.1 nM) low-capacity receptors in a particulate fraction from blood vessels and adrenals. Unrelated peptides did not displace atrial natriuretic factor. Fragments of atrial natriuretic factor displaced the labeled ligand with decreasing potency after cleavage at the N-terminal. The cleavage of the C-terminal tyrosine did not decrease the potency of atrial natriuretic factor, but further cleavage at the C-terminal dramatically reduced the affinity of the resulting peptides. The potency of the atrial natriuretic factor fragments in the radioligand assay was in proportion to their potency to inhibit aldosterone secretion by isolated rat glomerulosa cells. Our results suggest that these binding sites mediate the biological actions of atrial natriuretic factor in blood vessels and the adrenal, and that both receptors have similar specificities. ( Circ Res 56: 801-807, 1985) 
SUMMARY. Previous studies have shown that atrial natriuretic factor, a powerful vasorelaxant of precontracted vessels, inhibits the secretion of aldosterone stimulated by angiotensin II, adrenocorticotropic hormone, and potassium. We now report the presence of specific binding sites for atrial natriuretic factor in rat blood vessels (mesenteric and renal arteries) and adrenal capsules. Radioiodinated synthetic atrial natriuretic factor bound to a single class of high-affinity (K D = 0.1 nM) low-capacity receptors in a particulate fraction from blood vessels and adrenals. Unrelated peptides did not displace atrial natriuretic factor. Fragments of atrial natriuretic factor displaced the labeled ligand with decreasing potency after cleavage at the N-terminal. The cleavage of the C-terminal tyrosine did not decrease the potency of atrial natriuretic factor, but further cleavage at the C-terminal dramatically reduced the affinity of the resulting peptides. The potency of the atrial natriuretic factor fragments in the radioligand assay was in proportion to their potency to inhibit aldosterone secretion by isolated rat glomerulosa cells. Our results suggest that these binding sites mediate the biological actions of atrial natriuretic factor in blood vessels and the adrenal, and that both receptors have similar specificities. (Circ Res 56: [801] [802] [803] [804] [805] [806] [807] 1985) ATRIAL natriuretic factor (ANF) is a peptide identified recently in the atria of rats (De Bold et al., 1981; De Bold, 1982; Garcia et al., 1982) and other species (De Bold and Salerno, 1983; Nemeh and Gilmore, 1983; Trippodo et al., 1983) . ANF has been purified (Thibault et al., 1983; Grammer et al., 1983) , sequenced (Flynn et al., 1983; Currie et al., 1984; Seidah et al., 1984; Misono et al., 1984) and the cDNA sequence of its precursor determined (Maki et al., 1984; Yamanaka et al., 1984; Zivin et al., 1984) . Studies by Currie et al. (1983) and Grammer et al. (1983) demonstrated that ANF was a powerful vasorelaxant. Garcia et al. (1984) and Kleinert et al. (1984) found that ANF blocked the response of vascular strips to angiotensin II and norepinephrine. We therefore investigated the effects of ANF on the response of another target tissue of angiotensin II, the adrenal glomerulosa. We found that ANF blocked the stimulation of aldosterone secretion by angiotensin II in vitro (Chartier et al., 1984a) and in vivo in conscious rats (Chartier et al., 1984b) . ANF also blocked the aldosterone response to adrenocorticotropic hormone (ACTH) and potassium in vitro (Chartier et al., 1984a (Chartier et al., , 1984b . Atarashi et al. (1984) simultaneously reported similar effects on aldosterone production with an atrial extract. Thus ANF is not a selective blocker of any of these agents, but rather probably interferes with a common mechanism involved in the smooth muscle response to angiotensin II and norepinephrine and in the adrenal response to angiotensin II, ACTH, and potassium. In view of these results, we attempted to determine ANF binding sites in the vasculature and the adrenal capsules of the rat (Schiffrin et al., 1984) . Finally, since recent results suggest that ANF may act as a calcium channel blocker (Camargo et al., 1984) , we tested the cross-competition of ANF and calcium antagonists (nitrendipine, nifedipine, and verapamil) for the putative binding sites.
Methods

Materials
The nomenclature of ANF peptides is based on the sequence of the propeptide containing 128 amino acids (without the signal peptide) deduced from the rat cDNA sequence (Maki et al., 1984; Yamanaka et al., 1984; Zivin et al., 1984) . Synthetic ANF (Arg 101-Tyr 126), previously termed ANF 8-33 or ANF 48-73 based on the then known structure of the precursor peptides (ChartieT et al., 1984; Thibault et al., 1984a) , has the following amino acid sequence .
no
NHi-Arg-Arg-Ser-Ser-Cys-Phe-Gly-ay-Arg-Ile-Asp-Aig-ne--Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-COOH 115 120 125
Synthetic ANF was a generous gift of Dr. R.F. Nutt of Merck, Sharp and Dohme Research Laboratories. Atriopeptin II (ANF 103-124), DI (ANF 103-126) and human ANF (99-126) were purchased from Peninsula Laboratories. ANF (96-126) and ANF (54-126) were obtained from rat atria during purification of ANF (101-126) Thibault et al., 1984a) . N-terminal truncated peptides were produced from synthetic ANF by Edman degradation . C-terminal truncated peptides were obtained by treatment with various carboxypeptidases . The natriuretic and relaxant properties of these peptides have been defined .
ACTH was adrenocorticotropin 1-24 (Cortrosyn, Qrganon). Human angiotensin II (All) and (Arg 8 ) vasopressin (AVP) were purchased from Peninsula.
Iodination of Atrial Natriuretic Factor
Synthetic ANF was iodinated with iodine-125 by a modification of the chloramine-T method (Greenwood and Hunter, 1963) . Separation of radiolabeled ANF from free iodine was by immunoaffinity chromatography followed by C-18 reverse phase high pressure liquid chromatography. Specific activity measured by radioreceptor assay and selfdisplacement was approximately 1200-1300 Ci/mmol. ANF was also iodinated with iodine-127 and purified identically to 125 I-ANF. The mass of 127 I-ANF was determined by aminoadd analysis. The biological properties of ANF iodinated with iodine-127 were tested on aldosterone production by adrenal glomerulosa cells, on the precontracted chick rectum (Currie et al., 1983) , and the rabbit aorta (Garda et al., 1984) .
Preparation of Membranes
Sprague-Dawley rats weighing 300 g were killed by decapitation. The atria, ventricles, renal arteries, mesentery, and adrenals were processed for the binding studies. The mesenteric vascular bed was isolated as described . The adrenal capsules were separated by manual compression. The tissues were then immersed in 0.25 M sucrose solution, finely minced with scissors, homogenized in a Polytron (Kinematica; setting 8,10 seconds twice). The homogenate was centrifuged at 1,500 g for 10 minutes at 4°C; the supernatant was decanted and recentrifuged. The final supernatant was filtered through cheesecloth, then centrifuged at 104,000 g for 30 minutes. The pellet was resuspended in a 0.05 M Tris-HCl buffer, pH 7.4, containing 120 rriM NaCl, 5 ITIM MgCl 2 , 0.5 ITLM phenyl methyl sulfonyl fluoride (PMSF), 0.1% baritracin, and 1 HM aprotinin. Proteins were measured by the Coomassie blue method (Spector, 1978) . Next, bovine serum albumin was added at a concentration of 0.2%, and the membranes were diluted to a protein concentration of 0.25 to 1 mg/ml in the Tris-HCl buffer containing 0.2% albumin ("assay buffer").
123
I-ANF Binding Assay
The binding assay used 30-50 pM of labeled ANF and 10" 13 to 10" 6 M unlabeled ANF in competition experiments. In saturation experiments, increasing concentrations of 125 I-ANF (6-200 pM) were used, and nonspedfic binding was determined by incubation in the presence of 1 JIM unlabeled ANF for each point of saturation-binding curves. Incubation was done with 25-100 fig of receptor protein per tube, at 4°C for 60 minutes, since a plateau is achieved after 30 minutes. All assays were performed in duplicate. Separation of bound and free radioactivities was achieved by rapid filtration through polyethylenimine-treated Whatman GF/C filters (Bruns et al., 1983) soaked with 0.5 ml of 'assay buffer.' The filters were washed twice with 3 ml of 0.9% NaCl, then were allowed to dry and were counted in a Rackgamma LKB counter with 65% effidency. In studies in which nifedipine was used, tubes were protected from light.
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[IIJNitrendipine Binding Assay
This assay was identical to the ANF-binding assay, except that tubes were protected from light. The assay buffer contained 5 mM CaCl 2 . [ 3 H]nirrendipine was bought from New England Nuclear (specific activity 79.5 Ci/mmol). Nifedipine was kindly provided by Dr. David Frankel of Miles Laboratories, Canada.
Aldosterone Production by Isolated Rat Adrenal Cells
Isolated rat adrenal glomerulosa cells were prepared according to a modification of a technique previously described (Schiffrin et al., 1981) . Briefly, male Sprague-Dawley rats weighing 250 g were killed by decapitation, and the adrenal glands were immediately removed and dissected free of fat. Capsules were separated from fasdculata-reticularis by compression. The capsules were minced and incubated for 40 minutes at 37°C in medium 199 with Hanks' salts (Gibco) with sodium bicarbonate (0.35 g/liter) containing 80 Mg/ml Dispase (Boehringer Mannheim), 3 Mg/ml deoxyribonuclease I (Sigma Chemical Co.), 2 mg/ml collagenase type I (Sigma), and 2% bovine serum albumin. The cells were dispersed mechanically, filtered through a IOO-METI Nitex nylon filter (Tetko) and centrifuged at 200 g for 2 minutes. The cells were resuspended in medium 199 and preincubated for 2 hours at 37°C in a Dubnoff metabolic shaker in an atmosphere of 95% O 2 and 5% CO 2 . After centrifugation, they were resuspended in the same medium and incubated in the presence of the agents to be tested for 90 minutes. At the end of the incubation, the cell suspension was centrifuged and the supernatant was decanted into glass tubes and frozen at -20°C until assayed for aldosterone by radioimmunoassay (Schiffrin et al., 1981) .
Analysis of Data
Binding data was analyzed by computer assisted nonlinear regression analysis using the LJGAND program (Munson and Rodbard, 1980) for determination of density and affinity of binding sites. The ALLOT" program (De Lean et al., 1979) , based on the four-parameter logistic equation, was used to calculate the concentration of unlabeled ANF and related peptides inhibiting binding by 50% (IC50) in competition experiments. The inhibition constant (Ki) was calculated according to the method of Cheng and Prusoff (1973) 
Results
Specific binding of 125 I-ANF was found in the vasculature (mesenteric and renal arteries) and the adrenal capsule of the rat (Fig. 1) . Binding was saturable. A one-site model provided the best fit for the binding data. No statistically significant improvement of the fit was obtained with a two-site model. The density of binding sites (Bmox) calculated from competition curves was 95 ± 7 fmol/mg protein with a K D of 82 ± 7 pM in the mesenteric arteries (n = 5). In saturation experiments a B^ of 68 ± 22 fmol/mg protein (n = 2) and K D of 73 ± 11 pM were found. In renal arteries, the B^ detected was 23 ± 5 fmol/mg protein with a dissociation constant of 184 ± 86 pM (n = 5). In adrenal capsules, the B,,î n competition studies was 130 ± 22 fmol/mg, and the K D was 107 ± 26 pM (n = 5). Saturation data showed a B mxx of 90 ± 30 fmol/mg protein and K D of 64 ± 5 pM (n = 5). The similarity of data from competition and saturation experiments suggests that labeled and unlabeled ANF had similar behaviors in the binding assay. Indeed, we found that biological activity of ANF labeled with iodine-127 was conserved on the chick rectum and rabbit aorta by 70-100% (results not shown). On rat glomerulosa cells, I27 I-ANF was equipotent with unlabeled ANF in inhibiting basal aldosterone production (Fig. 2) .
Binding of labeled ANF was also examined in membranes prepared from rat atria, ventricles, and decapsulated adrenals. Only in the decapsulated adrenals did specific binding occur, but affinity was one-thirtieth that in adrenal capsules.
Degradation of labeled ANF during incubation was examined by reverse phase high pressure liquid chromatography (HPLC) (Fig. 3) . At 4°C and in the presence of batitracin, PMSF, and aprotinin, more 
FIGURE 2. Effect of synthetic unlabeled and i25 I-ANF on basal aldosterone production by rat adrenal glomerulosa cells.
than 90% of the labeled peptide was intact after a 60-minute incubation with mesenteric or adrenal membranes. Ninety-two percent of labeled ANF incubated with adrenal membranes and separated by centrifugation was found to bind to these membranes on re-incubation, in agreement with the HPLC elution profile of labeled ANF after incubation (Fig. 3) . The specificity of binding to mesenteric and adrenal membranes was demonstrated by the absence of displacement of labeled ANF competing with unrelated peptides such as angiotensin II (All), va- sopressin (AVP), or adrenocorticotropic hormone (ACTH) (1(T 7 to 10"* M). ANF-related peptides displaced labeled ANF with varying affinity (Fig. 4 ; Table 1 ). The cleavage of the N-terminal arginine of synthetic ANF (101-126) resulted in a peptide (ANF 102-126) which was less potent both in the mesenteric artery and the adrenal preparation by a factor of 4. Loss of the second arginine at the N-terminal end (ANF 103-126 or atriopeptin III) resulted in a dramatic loss of activity, by a factor of 20 in both preparations. Further splitting at the N-terminal end resulted in slight or no further loss of potency. The C-terminal tyrosine was unimportant for binding Cheng and Prusoff (1973) . and, if anything, affinity of the resulting ANF (101-125) was up to 50% higher. Further splitting at the C-terminal end produced a decrease in binding affinity. ANF (101-124), ANF (101-123), and ANF (101-121) were equipotent in both preparations, and about one-third as potent as ANF (101-126). Interestingly, human synthetic ANF (99-126) was slightly less potent in both preparations than the synthetic rat peptide. ANF (101-125) appears to contain the minimum core sequence active in these radioligand assays. The correlation coefficient of the Ki of these peptides in the mesenteric artery and adrenal capsule preparations was 0.93, suggesting that the adrenal and vascular receptors are identical. A-time course of binding of 1U 1-ANF to rat  mesenteric arteries at 4°C in a representative experiment. Concentration of la I-ANF was 0.07 nM with 0.5 mg/ml protein. Panel B:  association rate constant for binding of la l-ANF to mesenteric artery  membranes. The data from the experiment shown in panel A was  fitted to the second-order rate equation to obtain K+i. R, => B mo »  density of binding sites determined in a simultaneous competition  curve (14 pu). H« = total hormone present. B, = ANF bound at time  (t). Similar results were found in two other experiments. The inhibitory potency of four of these peptides on basal aldosterone secretion agreed with the data from the radioligand-binding experiments on adrenal capsular particulate fraction, as shown in Table  2 . This suggests that, indeed, these binding sites are involved in mediating the effects of ANF, at least on the adrenal glomerulosa.
The kinetics of binding of ANF were examined in association and dissociation experiments in membranes from mesenteric and adrenal capsules. On mesenteric artery membranes, the association rate constant at 4°C obtained by fitting the data to the second-order rate equation was 1.8 X 10 8 M/min (Fig. 5) . The dissociation rate constant at 4°C estimated by fitting the binding data to the pseudo-first order rate equation was 0.01/min (Fig. 6) . The K D at 4°C calculated from kinetic data was between 55 and 130 pM, in agreement with that obtained from steady state experiments. In adrenal capsules, kinetic data obtained (not shown) were similar, and kinetically determined K D agreed with the apparent equilibrium dissociation constant obtained by Scatchard analyses or from competition experiments.
The possibility that one of the mechanisms involved in the actions of ANF is an interference with calcium movements (Camargo et al., 1984) prompted us to test the hypothesis that ANF may be an endogenous Ugand of the receptors for calcium channel blockers. Neither nifedipine nor verapamil displaced labeled ANF in competition experiments with adrenal membranes. Unlabeled ANF did not compete with [ 3 HJnitrendipine for binding to the particulate fraction from adrenal capsules. The Ki of nifedipine in this assay was 3.1 riM and that of verapamil 8.8 MM (Fig. 7) . 
Discussion
Our results demonstrate the presence of specific high-affinity low-capacity receptors for atrial natriuretic factor in the vasculature (renal and mesenteric vessels) and the adrenal capsule of the rat. Lowaffinity specific binding was detectable in rat decapsulated adrenals, and no specific binding was detected in membranes from rat atria or ventricles. These results, together with the evidence that ANF is vasorelaxant (Currie et al., 1983; Grammer et al., 1983; Garcia et al., 1984) and inhibits the stimulated secretion of aldosterone (Atarashi et al., 1984 , Chartier et al., 1984a , suggests that the highaffinity binding sites we describe are involved in biological effects of ANF in these target organs. This hypothesis is further supported by the correlation which exists between the potency of ANF-related peptides to displace ANF from adrenal membranes and the potency of these peptides to inhibit basal aldosterone secretion. Taken together, our results lead us to propose a general bioregulatory role of ANF affecting the vasculature, the kidney, and adrenals. The generalized effects which resemble some of the actions of calcium blockers support the hypothesis that ANF may exert its effects by modulation of calcium fluxes. However, receptors for ANF are specific, and our results argue against a possible role of ANF as a putative endogenous ligand of receptors for calcium channel blockers.
The data obtained with ANF fragments suggest that ANF (101-125) contains the minimal core sequence of the peptide with potent biological activity on these preparations, since further cleavage at the C-or N-terminal amino acids reduces the potency from 3-to 10-fold. The result of the cleavage of the C-terminal tyrosine is interesting in that the potency of the resulting peptide is slightly increased, both on the binding assay and on the inhibition of aldosterone production, in agreement with the findings on natriuresis and relaxation of the chick rectum . The only important discrepancy between the binding and the effects on natriuresis and smooth muscle relaxation, resides in the actions of ANF (102-126). This peptide is as potent as ANF (101-126) on natriuresis and chick rectum relaxation , and relaxation of the precontracted rabbit aorta (Garcia et al., 1985) . Since the synthetic ANF is more potent in the radioligand-binding assay than in the dispersed glomerulosa cells (Charter et al., 1984a (Charter et al., , 1984b , these findings may result from differences in the rate of degradation in the bioassays (at 37°C) and the radioligand-binding assay (performed at 4°C in the presence of protease inhibitors). A similar explanation may apply to the surprising potency in both radioligand-binding assays (vascular and adrenal) of ANF (101-121), which is inactive on natriuresis and of intermediate potency on the chick rectum or the norepinephrine-contracted rabbit aorta (Garcia et al., 1985) .
During the final preparation of this publication, a report by Napier et al. (1984) demonstrated the presence of specific membrane receptors for ANF in rabbit aorta and rabbit and rat kidney cortex. The results in the rabbit are in close agreement with those we have obtained in the rat, and suggest that there may be similarities across species. Degradation of ANF during incubation may, however, be different in the rabbit and rat vasculature (Napier et al., 1984) .
In summary, we demonstrate the presence of vascular and adrenal binding sites for atrial natriuretic factor which mediate its effects on these target organs. Furthermore, our results indicate that vascular and adrenal binding sites for ANF have the same specificities for ANF fragments, and are probably similar receptors.
